Oncoinvent Announces Dosing of First Patient with Radspherin[® ]in Phase 1 Clinical Trial
Radiopharmaceutical company starts first-in-human trial in colorectal patients suffering from peritoneal carcinomatosisOncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies to provide new therapeutic options for cancer patients, today announced that the first patient has been dosed in the phase 1, first-in-human clinical trial of it’s lead candidate compound Radspherin[®]. “Radspherin[®] represents a promising new approach for treating patients with metastates to the peritoneal cavity from colorectal cancer that may potentially provide